# Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

> **NCT07527650** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 180 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- T2DM

## Interventions

- **DRUG:** HM15275
- **DRUG:** Placebo of HM15275

## Key facts

- **NCT ID:** NCT07527650
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527650, "Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07527650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*